Could removing the primary tumor boost survival in stage IV breast cancer with Bone-Only spread?

NCT ID NCT07687225

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial investigates whether surgically removing the primary breast tumor, followed by standard systemic therapy, improves survival compared to systemic therapy alone in women with stage IV breast cancer that has spread only to a single bone site. The study enrolls women aged 18 to 70 with newly diagnosed or first-line-treated disease. Researchers will track overall survival, cancer progression, quality of life, and treatment side effects over five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Primary tumor resection (surgery)
What this could lead to
If surgery plus systemic therapy improves survival, it could become a new standard approach for patients with stage IV breast cancer that has spread only to bone.
What could go wrong
This is a randomized trial, but the benefit of surgery in stage IV cancer is unproven. Surgery carries risks like infection or complications, and the cancer may still progress despite treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.